Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Anti-CD20
Bendamustine
COVID-19
Immunosuppressed patient
Lymphoma
Obinutuzumab
Rituximab
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
06
03
2023
accepted:
11
04
2023
medline:
23
10
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
People with hematologic malignancies have a significantly higher risk of developing severe and protracted forms of SARS-CoV-2 infection compared to immunocompetent patients, regardless of vaccination status. We describe two cases of prolonged SARS-CoV-2 infection with multiple relapses of COVID-19 pneumonia in patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. The aim is to highlight the complexity of SARS-CoV-2 infection in this fragile group of patients and the necessity of evidence-based strategies to treat them properly. Patients with hematological malignancies treated with bendamustine and anti-CD20 antibodies had a significant risk of prolonged and relapsing course of COVID-19. Specific preventive and therapeutic strategies should be developed for this group of patients.
Identifiants
pubmed: 37076752
doi: 10.1007/s15010-023-02039-2
pii: 10.1007/s15010-023-02039-2
pmc: PMC10115373
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
obinutuzumab
O43472U9X8
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1581Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28–33. https://doi.org/10.1038/s41591-020-01202-8 .
doi: 10.1038/s41591-020-01202-8
pubmed: 33442016
Oliva A, Curtolo A, Volpicelli L, Cancelli F, Borrazzo C, Cogliati Dezza F, et al. Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study. Infection. 2022;50:1373–82. https://doi.org/10.1007/s15010-022-01869-w .
doi: 10.1007/s15010-022-01869-w
pubmed: 35781785
pmcid: 9251021
Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223:23–7. https://doi.org/10.1093/infdis/jiaa666 .
doi: 10.1093/infdis/jiaa666
pubmed: 33089317
Sepulcri C, Dentone C, Mikulska M, Bruzzone B, Lai A, Fenoglio D, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient—a case study. Open Forum Infect Dis. 2021;8:ofab217. https://doi.org/10.1093/ofid/ofab217 .
doi: 10.1093/ofid/ofab217
pubmed: 34796242
pmcid: 8135455
Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. https://doi.org/10.1136/bmj-2021-068632 .
doi: 10.1136/bmj-2021-068632
pubmed: 35236664
Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, et al. Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Adv. 2022;6:1537–46. https://doi.org/10.1182/bloodadvances.2021006917 .
doi: 10.1182/bloodadvances.2021006917
pubmed: 35114690
pmcid: 8816838
Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57:512–9. https://doi.org/10.3109/10428194.2015.1110748 .
doi: 10.3109/10428194.2015.1110748
pubmed: 26696321
Davies A, Kater AP, Sharman JP, Stilgenbauer S, Vitolo U, Klein C, et al. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol. 2022;18:2943–66. https://doi.org/10.2217/fon-2022-0112 .
doi: 10.2217/fon-2022-0112
pubmed: 35856239
Salles G, Barrett M, Foà R, Maurer J, O’Brien S, Valente N, et al. Rituximab in B-Cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34:2232–73. https://doi.org/10.1007/s12325-017-0612-x .
doi: 10.1007/s12325-017-0612-x
pubmed: 28983798
pmcid: 5656728
Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M, et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol. 2021;26:826–34. https://doi.org/10.1007/s10147-021-01863-6 .
doi: 10.1007/s10147-021-01863-6
pubmed: 33486624
pmcid: 7826293
Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26:1218–23. https://doi.org/10.1038/s41591-020-0979-0 .
doi: 10.1038/s41591-020-0979-0
pubmed: 32581323
pmcid: 7785283
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–92. https://doi.org/10.1182/blood.2020008824 .
doi: 10.1182/blood.2020008824
pubmed: 33113551
pmcid: 7746126
Re D, Barrière J, Chamorey E, Delforge M, Gastaud L, Petit E, et al. Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies. Leuk Lymphoma. 2021;62:3308–10. https://doi.org/10.1080/10428194.2021.1957877 .
doi: 10.1080/10428194.2021.1957877
pubmed: 34308748
Marchesi F, Pimpinelli F, Giannarelli D, Ronchetti L, Papa E, Falcucci P, et al. Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas. Leukemia. 2022;36:588–90. https://doi.org/10.1038/s41375-021-01418-8 .
doi: 10.1038/s41375-021-01418-8
pubmed: 34545184
Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10:985–96. https://doi.org/10.1016/S2213-2600(22)00180-1 .
doi: 10.1016/S2213-2600(22)00180-1
pubmed: 35688164
pmcid: 9173721
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–408. https://doi.org/10.1056/NEJMoa2118542 .
doi: 10.1056/NEJMoa2118542
pubmed: 35172054
Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech A-M, Lane C, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis. 2020;222:1103–7. https://doi.org/10.1093/infdis/jiaa446 .
doi: 10.1093/infdis/jiaa446
pubmed: 32702095
Camprubí D, Gaya A, Marcos MA, Martí-Soler H, Soriano A, Mosquera MDM, et al. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir. Int J Infect Dis. 2021;104:379–81. https://doi.org/10.1016/j.ijid.2020.12.050 .
doi: 10.1016/j.ijid.2020.12.050
pubmed: 33359065
Shafat T, Grupel D, Porges T, Levi I, Yagel Y, Nesher L. Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19. Br J Haematol. 2022;198:826–9. https://doi.org/10.1111/bjh.18315 .
doi: 10.1111/bjh.18315
pubmed: 35718461
Percival MEM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, et al. Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the seattle strategy. JCO Oncol Pract. 2020;16:571–8. https://doi.org/10.1200/OP.20.00241 .
doi: 10.1200/OP.20.00241
pubmed: 32369409
pmcid: 7489485